Published in final edited form as:

J Am Chem Soc. 2012 August 22; 134(33): 13562–13564. doi:10.1021/ja305532y.

C4-Alkoxy-HPD: a Potent Class of Synthetic Modulators Surpassing Nature in AI-2 Quorum Sensing

Kyoji Tsuchikama, Jie Zhu, Colin A. Lowery, Gunnar F. Kaufmann, and Kim D. Janda*

The Skaggs Institute for Chemical Biology and Departments of Chemistry, Immunology & Microbial Science, and Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States

Abstract

Bacteria have developed cell-to-cell communication mechanisms, termed quorum sensing (QS), which regulate bacterial gene expression in a cell population-dependent manner. Autoinducer-2 (AI-2), a class of QS signaling molecules derived from (4*S*)-4,5-dihydroxy-2,3-pentanedione (DPD), has been identified in both Gram-negative and Gram-positive bacteria. Despite considerable interest in the AI-2 QS system, the biomolecular communication used by distinct bacterial species still remains shrouded. Herein we report the synthesis and evaluation of a new class of DPD analogs, C4-alkoxy-5-hydroxy-2,3-pentanediones, termed C4-alkoxy-HPDs. Remarkably, two of the analogs were more potent QS agonists than the natural ligand, DPD, in *Vibrio harveyi*. The findings presented extend insights into ligand-receptor recognition/signaling in the AI-2 mediated QS system.

Bacteria have developed unique systems to coordinate their behavior in a cell density-dependent manner, a process that has been termed quorum sensing (QS).^{1,2} QS is mediated by a series of signal production/secretion/response events utilizing diffusible signaling molecules called autoinducers. When the bacterial population, and thus concentration of autoinducer reaches a threshold level, gene expression is synchronized in a concerted manner. In many species, this process often results in pathogenic events such as biofilm formation and virulence factor production. Therefore, the modulation of QS has emerged as a potential therapeutic approach for combating microbial infection.^{3–6}

Autoinducer-2 (AI-2), one of the classes of autoinducers, is produced by both Gram-negative and Gram-positive bacterial species.^{7–10} AI-2 signaling molecules share a single common precursor, (4*S*)-4,5-dihydroxy-2,3-pentanedione (DPD), that exists in a multiplexed equilibrium between its linear and cyclic forms (Figure 1).¹¹ Collectively, these findings have led to the hypothesis that bacteria use AI-2 as a “universal language” for interspecies monitoring as well as intraspecies communication.¹⁰

Our group and others have reported upon the synthesis and potency of a series of DPD analogs including C1-alkyl-DPDs,^{12–16} 2,5-dihydroxy-2-methylcyclopentanones (DHMPs),¹⁷ and C5-methyl-DPDs¹⁸ as QS modulators (Figure 2). In sum, these reports have provided evidence that minor structural alterations of DPD can have a significant impact upon the function of AI-2 in QS mediated processes. However, even with these studies a clear gap still exists between our understanding of DPD’s complex chemical

*Corresponding Author, kdjanda@scripps.edu.

ASSOCIATED CONTENT

Supporting Information. Synthetic protocols, assay methods, additional biological assays, and characterization of new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

equilibrium and leveraging structural information for agonist/antagonist design between bacterial species.¹¹

To help better define the chemical determinants critical within the sphere of the AI-2 QS system, we were drawn to the QS activity seen with the C1-alkyl derivatives, particularly their oscillatory agonist/antagonist activity based upon the addition of single methylene units. Thus, we designed and synthesized a new group of synthetic DPD analogs, C4-alkoxy-5-hydroxy-2,3-pentanedione (C4-alkoxy-HPD, Figure 2). In this communication, we present data demonstrating that these C4-alkoxy-HPDs are capable of more potent QS agonism than the natural signal used in *Vibrio harveyi*.

The synthesis of the C4-alkoxy-HPDs is shown in Scheme 1, which began from readily available racemic 1-((*tert*-butyldimethylsilyl)oxy)pent-3-yn-2-ol (**1**).¹⁹ Alkyl groups (methyl, ethyl, propyl, hexyl, and benzyl) were installed on the C4-hydroxy group under standard conditions of ether synthesis; however, incomplete consumption of the starting material and significant degradation of substrate and products were observed and propargyl ethers **2a–e** were obtained in low to moderate yields. Subsequently, ruthenium-catalyzed oxidation of ethers **2a–e** was accomplished to give diketones **3a–e**. Finally, precursors **3a–e** were solubilized in dilute sulfuric acid to afford C4-alkoxy-HPDs **4a–e** in quantitative yield. NMR analysis of compounds **4a–e** showed that they exist as a mixture of linear/cyclic forms in a ratio approximately 10:90. Given the reported linear/cyclic ratio of DPD (approximately 20:80),^{11,20,21} these results illustrate that installation of “capping” substituents on the C4-hydroxy group within DPD does not significantly impact cyclization.

The obtained C4-alkoxy-HPDs **4a–e** were evaluated for the modulation of QS signaling using two established reporter assays: bioluminescence emission in *V. harveyi*²² and induction of β -galactosidase expression in *Salmonella enterica* serovar Typhimurium.²³ First, we examined the effects of the synthetic analogs on bioluminescence of the *V. harveyi* strain MM32 (ATCC BAA-1117, $\Delta luxS$, $\Delta luxN$), a strain unable to produce its own DPD due to the lack of the LuxS synthase and lacking the acylhomoserine lactone receptor LuxN. The use of this strain allows for the measurement of QS responses only *via* the AI-2 pathway in the presence of exogenous autoinducers. Cultures were incubated in the presence of DPD or each synthetic analog at varying concentrations (20–0.02 μ M).

Analog **4a–c** induced bioluminescence emission, whereas C4-HexO-HPD **4d** and C4-BnO-HPD **4e** exhibited weak or no induction at 20 μ M (Figure 3). The induction was strongly dependent on the length of the C4-hydroxy alkylation. Thus, while C4-MeO-HPD **4a** presented modest QS activity, remarkably, C4-EtO-HPD **4b** and C4-PrO-HPD **4c** appeared to be better ligands than DPD. Notably, analog **4c**, a racemate, was almost 10-fold more potent than the natural ligand DPD with a submicromolar EC₅₀ value of $0.15 \pm 0.03 \mu$ M, whereas the EC₅₀ value of DPD was $1.07 \pm 0.06 \mu$ M under our assay conditions (Table 1).²⁴ It is reasonable to speculate that a single enantiomer of analog **4c** may provide even greater enhanced activity.

To our knowledge, these compounds are the first examples of synthetic DPD analogs that are better at initiating an AI-2 mediated process than the natural ligand.²⁵ In AI-2 based QS of *V. harveyi*, it is a borate diester derived from the cyclic isomer (2*S*,4*S*)-THMF that the periplasmic AI-2 receptor protein LuxP recognizes (Figure 1), which triggers a protein phosphorylation cascade that ultimately results in altered gene expression.^{26,27} With this mechanism in mind, the slightly higher ratio of cyclic forms in the equilibrium of C4-alkoxy-HPDs (Scheme 1) may help drive their enhanced activity; however, this is unlikely to be the sole contributing factor given the varying agonist activity of a panel of C4-alkoxy-HPDs. We surmise that LuxP has an additional structural hydrophobic modulatory site,

which analog **4c** has advantageously accessed to produce superior QS activity. Indeed, a docking model of LuxP and analog **4c** appears to support our speculation (Figure S5).²⁸ On the other hand, congeners with large hydrophobic groups such as the hexyl (**4d**) and benzyl (**4e**) derivatives may be too bulky for a productive interaction.

To continue our studies, analogs **4a–e** were screened for QS modulation in *S. Typhimurium* strain Met844 (*lsr-lacZ* fusion, $\Delta luxS$), a strain incapable of producing its own DPD.²⁹ The *lsr-lacZ* fusion encodes β -galactosidase under the AI-2-regulated *lsr* promoter, and enables the monitoring of AI-2-dependent *lsr* expression based on the residual β -galactosidase activity. Assays were performed using the analogs at 50 μ M in the absence of DPD (agonist assay) or in the presence of 50 μ M DPD (antagonist assay). These experiments revealed no significant agonist or antagonist activity (Table 1 and Figure S3). This is in contrast to our previous report on a panel of C1-alkyl-DPD analogs, in which several compounds exhibited antagonist effects in AI-2 based QS of *S. Typhimurium*.^{12,15,16}

In the AI-2 QS circuit of *S. Typhimurium*, DPD is transported into the cytoplasm and the C5-hydroxy group is phosphorylated by the DPD kinase LsrK to afford the chemical species responsible for regulating gene expression.^{30,31} A recent report highlights how LsrK also phosphorylates a series of unnatural C1-alkyl-DPDs to provide active modulators of QS acting on the *lsr* operon.¹⁵ For the purpose of further dissecting the lack of analog activity, LsrK-mediated phosphorylation assays of C4-alkoxy-HPDs were performed (Figure 4 and S4). As anticipated based on their QS inactivity, none of the analogs were phosphorylated by LsrK, suggesting that the C4-hydroxy group in DPD is a critical factor in the mechanism of the LsrK-mediated phosphorylation.

In conclusion, we have detailed the synthesis of a panel of DPD derivatives, C4-alkoxy-HPDs. These DPD analogs were evaluated for the modulation of bacterial QS in established assays, and unanticipated, yet, remarkable effects on AI-2 QS circuits were observed in a species-dependent manner. Indeed, the present work describes the discovery of the most potent agonist of natural or synthetic ligands known for *V. harveyi* QS signaling. While potent antagonistic activity was not uncovered with this series of structures, the nuance between agonist and antagonist is a fine line and thus our findings should enable future chemical structure-based approaches for accessing such alternative activity. In a broader sense, the present work, coupled with previous findings with C1-alkyl-DPD analogs, highlights how manipulation of the DPD scaffold can provide valuable tools for in-depth studies of the ligand-receptor interactions making up AI-2-mediated QS.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge Prof. Bonnie Bassler (Princeton University) for providing us with *S. Typhimurium* strain Met844, Dr. Daniel Globisch for the LuxP-analog docking model, and Dr. Karen C. McCague for insightful discussion. We also acknowledge financial support from the NIH (Grant AI077644 to K.D.J.), the Skaggs Institute for Chemical Biology, and the Japan Society for the Promotion of Science (fellowship to K.T.).

REFERENCES

1. Engebrecht J, Nealson K, Silverman M. Cell. 1983; 32:773–781. [PubMed: 6831560]
2. Fuqua WC, Winans SC, Greenberg EP. J. Bacteriol. 1994; 176:269–275. [PubMed: 8288518]
3. Suga H, Smith KM. Curr. Opin. Chem. Biol. 2003; 7:586–591. [PubMed: 14580562]

4. Bjarnsholt T, Jensen PO, Rasmussen TB, Christophersen L, Calum H, Hentzer M, Hougen HP, Rygaard J, Moser C, Eberl L, Hoiby N, Givskov M. *Microbiology*. 2005; 151:3873–3880. [PubMed: 16339933]
5. Lowery CA, Salzameda NT, Sawada D, Kaufmann GF, Janda KD. *J. Med. Chem.* 2010; 53:7467–7489. [PubMed: 20669927]
6. Zhu P, Li M. *Curr. Med. Chem.* 2012; 19:174–186. [PubMed: 22320296]
7. Bassler BL, Wright M, Silverman MR. *Mol. Microbiol.* 1994; 13:273–286. [PubMed: 7984107]
8. Bassler BL, Greenberg EP, Stevens AM. *J. Bacteriol.* 1997; 179:4043–4045. [PubMed: 9190823]
9. Vendeville A, Winzer K, Heurlier K, Tang CM, Hardie KR. *Nat. Rev. Microbiol.* 2005; 3:383–396. [PubMed: 15864263]
10. Waters CM, Bassler BL. *Annu. Rev. Cell. Dev. Biol.* 2005; 21:319–346. [PubMed: 16212498]
11. Globisch D, Lowery CA, McCague KC, Janda KD. *Angew. Chem. Int. Ed. Engl.* 2012; 51:4204–4208. [PubMed: 22378693]
12. Lowery CA, Park J, Kaufmann GF, Janda KD. *J. Am. Chem. Soc.* 2008; 130:9200–9201. [PubMed: 18576653]
13. Lowery CA, Abe T, Park J, Eubanks LM, Sawada D, Kaufmann GF, Janda KD. *J. Am. Chem. Soc.* 2009; 131:15584–15585. [PubMed: 19824634]
14. Ganin H, Tang X, Meijler MM. *Bioorg. Med. Chem. Lett.* 2009; 19:3941–3944. [PubMed: 19394822]
15. Roy V, Smith JA, Wang J, Stewart JE, Bentley WE, Sintim HO. *J. Am. Chem. Soc.* 2010; 132:11141–11150. [PubMed: 20698680]
16. Gamby S, Roy V, Guo M, Smith JA, Wang J, Stewart JE, Wang X, Bentley WE, Sintim HO. *ACS Chem. Biol.* 2012; 7:1023–1030. [PubMed: 22433054]
17. Tsuchikama K, Lowery CA, Janda KD. *J. Org. Chem.* 2011; 76:6981–6989. [PubMed: 21678949]
18. Rui F, Marques JC, Miller ST, Maycock CD, Xavier KB, Ventura MR. *Bioorg. Med. Chem.* 2012; 20:249–256. [PubMed: 22137598]
19. Mohamed YAM, Inagaki F, Takahashi R, Mukai C. *Tetrahedron*. 2011; 67:5133–5141.
20. Meijler MM, Hom LG, Kaufmann GF, McKenzie KM, Sun C, Moss JA, Matsushita M, Janda KD. *Angew. Chem. Int. Ed. Engl.* 2004; 43:2106–2108. [PubMed: 15083457]
21. Semmelhack MF, Campagna SR, Federle MJ, Bassler BL. *Org. Lett.* 2005; 7:569–572. [PubMed: 15704896]
22. Taga ME, Xavier KB. *Curr. Protoc. Microbiol.* 2011; Chapter 1 Unit1C.1.
23. Griffith KL, Wolf RE Jr. *Biochem. Biophys. Res.* 2002; 290:397–402.
24. A similar EC₅₀ value of DPD was reported: Winzer K, Hardie KR, Burgess N, Doherty N, Kirke D, Holden MT, Linforth R, Cornell KA, Taylor AJ, Hill PJ, Williams P. *Microbiology*. 2002; 148:909–922. [PubMed: 11932438]
25. (4*S*,5*R*)-4,5-Dihydroxy-2,3-hexanedione (ref 18) was the most potent agonist of the synthetic analogs reported to date in QS of *V. harveyi*, although it showed approximately 10-fold higher EC₅₀ value than that of DPD.
26. Neiditch MB, Federle MJ, Pompeani AJ, Kelly RC, Swem DL, Jeffrey PD, Bassler BL, Hughson FM. *Cell*. 2006; 126:1095–1108. [PubMed: 16990134]
27. Chen X, Schauder S, Potier N, Van Dorsselaer A, Pelczar I, Bassler BL, Hughson FM. *Nature*. 2002; 415:545–549. [PubMed: 11823863]
28. The existence of an additional cavity proximal to the DPD binding site within LuxP has also been discussed in ref 18.
29. Taga ME, Miller ST, Bassler BL. *Mol. Microbiol.* 2003; 50:1411–1427. [PubMed: 14622426]
30. Xavier KB, Miller ST, Lu W, Kim JH, Rabinowitz J, Pelczar I, Semmelhack MF, Bassler BL. *ACS Chem. Biol.* 2007; 2:128–136. [PubMed: 17274596]
31. Xue T, Zhao L, Sun H, Zhou X, Sun B. *Cell Res.* 2009; 19:1258–1268. [PubMed: 19636340]

Figure 1.
A plausible equilibrium of DPD in aqueous solution.

Figure 2.
Structures of DPD analogs for the modulation of AI-2 based QS.

Figure 3.

Bioluminescence of *V. harveyi* strain MM32 ($\Delta luxN$, $\Delta luxS$) in the presence of the analogs. Bioluminescence was normalized to cell density. All assays were performed in triplicate, and error bars represent standard deviation. All curves were fit to variable-slope sigmoidal curves using GraphPad Prism® software. BnO-HPD **4e** showed no agonistic effect at 20 μM .

Figure 4.
LsrK-mediated phosphorylation assays.

Scheme 1.
Synthesis of C4-alkoxy-HPDs **4a-e**.

Table 1Summary of QS modulation by C4-alkoxy-HPDs^a

compound (C4-RO-HPD)	EC ₅₀ in <i>V. harveyi</i> assay (mean ± SD, μM) ^b	β-galactosidase activity in <i>S. Typhimurium</i> (mean ± SD, %) ^c
(4 <i>S</i>)-DPD	1.07 ± 0.06	100.0 ± 2.9
R = Me (4a)	7.60 ± 0.45	<5
R = Et (4b)	0.79 ± 0.05	<5
R = Pr (4c)	0.15 ± 0.03	<5
R = Hex (4d)	N.D.	<5
R = Bn (4e)	N.D.	<5

^a All assays were performed in triplicate.^b All EC₅₀ values were calculated from the sigmoidal curves obtained in Figure 3.^c Assays were performed in the presence of 50 μM compound. SD, standard deviation; N.D., not determined.